ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Consumer Staples / PETS / dividends
YI (37) RDGT (36) GRDN (71) CVS (60) ⌘ Pro Terminal →

PetMed Express Inc. (PETS) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.20 +0.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.20

PetMed Express Inc. (PETS) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $25.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PETS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PETS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, PetMed Express Inc. (NASDAQ: PETS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.20 (+0.84% 1D, market cap $25.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 147 tracked Consumer Staples issuers, PETS ranks #145 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PETS compare to YI and RDGT in the Consumer Staples sector?
▼

Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), PETS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -35.0%. By comparison, YI (111 Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $25.1M) and RDGT (Ridgetech Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC —, cap $2.9M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PETS?
▼

Per PETS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001040130), PetMed Express Inc. generated $179.0M in revenue (-21.1% YoY), -$57.3M in net income, and -$33.0M in free cash flow against $88.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.20 (-0.04%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510019
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (3)SEC (3)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.5% Base Target
$4 Bull$1 Base$1 Bear
📬 FREE PETS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PETS)Realized 20D OHLCV Swing Band: ±7.5%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY PETS SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+6/20 pts (32% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 35.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 28.1% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
27
Grade E$1.27-5.5% Next Q
Q2 (-2Q)
24
Grade E$1.20-1.7% Next Q
Q3 (-1Q)
22
Grade E$1.18+1.7% Next Q
Current
19
Grade E$1.20-12% Hist 90D α
Trajectory: E (27) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PETS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PETS currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Consumer Staples with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.46) and Max Pain ($1.26) forces dealer call-delta covering toward $4.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PETS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PETS Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 19%NO 81%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.88% Total Yield
0.08% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
88/100 • FORTRESS PAYOUT
FREE CASH FLOW PAYOUT RATIO
14% of FCF
8 consecutive years of payout growth
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $321/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PETS)

  • ✓Walkthrough of PETS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PETS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.14%▼ DESCENDING CHANNEL
2026-11-03O $1.18H $1.20L $1.18C $1.20VOL 42.4K
RES: $1.48SUP: $1.03SMA50: $1.46SMA200: $2.09
$2.86$2.40$1.93$1.47$1.01RES $1.48SUP $1.03$1.202026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PETS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PETS Butterfly Map → + Track PETS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -21.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PETS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PETS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PETS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PETS)

Consumer Staples Rank #145 of 147 ⚔️ YI vs PETS Full Matrix →

1. Head-to-Head Consumer Staples Peer Comparison (PETS vs. YI, RDGT, GRDN, CVS)

Industry: Retail-Drug Stores and Proprietary Stores (5 Tracked Issuers)

Across 147 tracked Consumer Staples securities in the Roarable RQD universe, PetMed Express Inc. (PETS) ranks #145 by composite RQD confidence (19/100, grade E) and #117 by equity capitalization ($25.8M). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with PETS at 19/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PETS ACTIVE
PetMed Express Inc.
E 19/100 — 28.1% -35.0% +0.84% $25.8M Benchmark Subject
YI
111 Inc.
D- 37/100 — 5.8% -20.5% +2.46% $25.1M /yi-vs-pets →
RDGT
Ridgetech Inc.
D- 36/100 — 3.6% — +0.88% $2.9M /rdgt-vs-pets →
GRDN
Guardian Pharmacy Services Inc. (Class A)
B- 71/100 52.1x 20.2% 37.7% -1.70% $2.58B /grdn-vs-pets →
CVS
CVS Health Corporation
C- 60/100 65.3x 45.0% 2.6% -1.93% $115.43B /cvs-vs-pets →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001040130 ↗

In its most recent audited fiscal period (FY2025, filed 2026-03-31), PetMed Express Inc. (PETS) reported GAAP revenue of $179.0M (-21.1% vs. FY2024 revenue of $227.0M , and -34.7% cumulative change since FY2023) , GAAP net income of -$57.3M, operating cash flow of -$28.4M, and free cash flow of -$33.0M (-8256.7% YoY). On the balance sheet, PETS closed FY2025 with $88.0M in total assets against $0 in total debt (Altman Z-Score: 0.24, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-03-31 $179.0M -$57.3M -$28.4M -$33.0M $88.0M —
FY2024 (FY) 2025-03-31 $227.0M -$6.3M $4.7M -$395.0K $144.8M —
FY2023 (FY) 2024-03-31 $274.1M -$7.5M $4.3M $4.3M — —

3. PETS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PETS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, PetMed Express Inc. (NASDAQ: PETS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.20 (+0.84% 1D, market cap $25.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 147 tracked Consumer Staples issuers, PETS ranks #145 in composite RQD confidence.

How does PETS compare to YI and RDGT in the Consumer Staples sector?

Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), PETS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -35.0%. By comparison, YI (111 Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $25.1M) and RDGT (Ridgetech Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC —, cap $2.9M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PETS?

Per PETS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001040130), PetMed Express Inc. generated $179.0M in revenue (-21.1% YoY), -$57.3M in net income, and -$33.0M in free cash flow against $88.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PETS trading relative to its 50-day, 200-day, and 52-week technical levels?

PETS last traded at $1.20 (+0.84% on volume of 34,885 shares), positioning the stock -17.81% below its 50-day simple moving average ($1.46) and -42.58% below its 200-day simple moving average ($2.09). Across its 52-week range of $1.15 to $4.10, PETS sits at the 1.7% percentile with a 14-day RSI of 35.2 (NEUTRAL RANGE) and an implied next-earnings move of ±7.5% ($1.11 to $1.29).

Direct Sub-Reports: PETS RQD Cockpit PETS 12M Forecast PETS Earnings & Move PETS Dividends & DRIP PETS Insiders & 13F PETS Whale Options PETS Profit Sankey PETS News & Why
ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ SEC XBRL & RQD VERIFIED

PETS — PetMed Express Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-03-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PetMed Express Inc. (PETS) earns a live Roarable RQD composite score of 19/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.20 (+0.84% 1D, market capitalization $25.8M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 28.1%, operating margin of -32.8%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.24, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

PetMed Express Inc. Is a NASDAQ-listed issuer classified under the Consumer Staples sector and the Retail-Drug Stores and Proprietary Stores industry. The source profile identifies the company as operating in this industry with a market capitalization of $0.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), PetMed Express Inc. (PETS) reported $179.0M in annual revenue (up from $227.0M in FY2024, -21.1% YoY) and -$57.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($274.1M revenue, -$7.5M net income) through FY2025, PETS scaled operating cash flow to -$28.4M and free cash flow to -$33.0M, backed by $88.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 19/100): Established market leader in Consumer Staples with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.15 – $4.10 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -32.8% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph records no upstream or downstream links and no proprietary signals, so supplier, customer, and sector-correlation dependencies cannot be identified from the source data.

  • Key Question #1: Can PETS sustain or expand its -32.8% operating margin and -35.0% ROIC against Retail-Drug Stores and Proprietary Stores peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $179.0M and free cash flow of -$33.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PETS's equity valuation to Consumer Staples capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PETS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PetMed Express Inc. (PETS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PETS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PETS Bull vs. Bear Conversation Board — What's Your Call at $1.20?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PETS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PETS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.46 (+22.7%)
📌 Pinned Debate

The stock trades near its 52-week low at $1.18 with a $25.6M market cap, leaving room for a rebound if cash generation improves from it

The street is overcomplicating PetMed Express Inc. (PETS). The stock trades near its 52-week low at $1.18 with a $25.6M market cap, leaving room for a rebound if cash generation improves from its current 0% FCF yield.. With an RQD score of 19/100 (E) and Forensic Balance Sheet at 2/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.29.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 3/20 institutional whale-flow stock at $1.19 is dangerous when funds are rotating into Consumer Staples.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.95 (-20.2%)
Spot @ $1.19

Negative ROIC of -35%, an Altman Z of 0.24, and a Piotroski F of 2/9 signal elevated forensic and balance-sheet distress risk.

I respect the product at PetMed Express Inc., but the stock at $1.19 is a different story. Negative ROIC of -35%, an Altman Z of 0.24, and a Piotroski F of 2/9 signal elevated forensic and balance-sheet distress risk.. FCF yield is 0.0% and RQD sits at 19/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%